Skip to main content

In Brief This Week: Quest Diagnostics, Sygnis, and Exact Sciences

NEW YORK (360Dx) – Quest Diagnostics and MediExcel Health Plan, a California-licensed health maintenance organization that specializes in cross-border healthcare, this week announced the opening of the first Quest specialized lab in Tijuana, Mexico, inside MediExcel’s Excel Hospital.

They noted that because of the partnership, Excel Hospital physicians and MediExcel members will benefit from access to a broader range of testing services that will include advanced diagnostic capabilities only provided by Quest.


Sygnis said that it has completed its acquisition of Innova Biosciences, a privately held UK-based bioconjugates company. Sygnis paid €10.8 million ($12.2 million), consisting of €8 million in cash and 2 million Sygnis shares.

Depending on agreed performance indicators, the purchase price will also include up to 1.5 million shares issued as convertible bonds.

Sygnis, which has offices in Madrid, Spain, and Germany, announced its plan in May to acquire Innova, which develops, manufactures, and commercializes labelling reagents. Sygnis noted that its labeling technologies complement its genomic and proteomics workflows.


Exact Sciences said in a document filed with the US Securities and Exchange Commission that the underwriters of its previously announced public offering exercised their overallotment option by purchasing an additional 450,000 shares of the company’s common stock at $35 per share. As a result, the net proceeds from the offering totaled $23.4 million.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.